Examples of Nordic Fund X Epsilon in a sentence
Bidco is a newly incorporated company established under the laws of Jersey, formed by or on behalf of Nordic Fund X Epsilon, for the purpose of undertaking the Acquisition.
In connection with its financing of Bidco, Nordic Fund X Epsilon has entered into the Equity Commitment Letter.
As a result of the Sale Process, ADVANZ PHARMA received expressions of interest and non-binding offers for the company, including a non-binding offer from Nordic Fund X Epsilon, each of which was considered by the ADVANZ PHARMA Board with Jefferies.On 8 December 2020, the ADVANZ PHARMA Board announced that it was in advanced discussions with Nordic Fund X Epsilon to acquire the entire issued, and to be issued, limited voting share capital of ADVANZ PHARMA.
These obligations will remain in force until the earlier of (i) 15 October 2022 or (ii) the completion of a definitive agreement between Nordic Fund X Epsilon and ADVANZ PHARMA in connection with the Acquisition.
A copy must also be sent to the Takeover Panel’s Market Surveillance Unit by email (monitoring@disclosure.org.uk).Enquiries:BidcoNordic Fund X Epsilon Tel: +46 8 440 50 50 Katarina Janerud Morgan Stanley & Co. International plc Tel: +44 20 7425 8000 (Financial Adviser to Bidco and Nordic Fund X Epsilon) David Kitterick Siddhart Nahata Alberto Bertani ADVANZ PHARMA Corp.
White & Case LLP and Appleby (Jersey) LLP and Fasken Martineau DuMoulin LLP are retained as legal advisers to ADVANZ PHARMA.Important Notices about Financial AdvisersMorgan Stanley & Co. International plc (“Morgan Stanley”) are acting as financial advisors to Nordic Fund X Epsilon and to no one else.
Appendix IV Details on the Topco Group and the Topco B Shares Part A Information on Topco and the Intermediate Holding Companies Topco is indirectly owned by Nordic Fund X Epsilon, through Nordic Holdco.
Topco GroupTopco is indirectly owned by Nordic Fund X Epsilon, through Nordic Holdco.
The cash consideration payable to ADVANZ PHARMA Shareholders for the ADVANZ PHARMA Shares pursuant to the terms of the Acquisition will be funded by funds to be invested indirectly in Bidco by Nordic Fund X Epsilon and certain other investment funds managed or advised by Nordic Capital affiliates.
Confidentiality AgreementNordic Fund X Epsilon and ADVANZ PHARMA entered into a confidentiality agreement on 15 October 2020 (the “Confidentiality Agreement”) pursuant to which Nordic Fund X Epsilon has undertaken, among other things, to keep confidential information relating to ADVANZ PHARMA and not to disclose it to third parties (other than permitted recipients) unless, among other circumstances, required by law or regulation or at the request of applicable regulatory or governmental organisations.